Abstract:LB-115 Mitochondrial malfunction, which can lead to decreased ATP generation through oxidative phosphorylation and altered drug sensitivity, has long been observed in many cancer cells, but the underlying mechanisms remain to be investigated. Here we report the establishment of an inducible cell model in which the mitochondrial respiratory function can be controlled by tetracycline and the use of this system as a tool to investigate on the relationship between mitochondrial respiratory malfunction, redox alterations, and drug sensitivity. A dominant negative form of the DNA polymerase gamma (POLGdn) was expressed in the T-ReX293 tetracycline inducible system. Mitochondrial malfunction was induced by doxocycline, which led to a almost complete suppression of oxygen consumption, caused by a depletion of the mitochondrial DNA-encoded respiratory chain complex I, III, IV, and V components, despite an increase of nuclear encoded complex II subunit proteins. Accompany with this mitochondrial respiratory defect, superoxide generation from the respiratory chain decreased, whereas cellular hydrogen peroxide level increased, as shown by fluorometric detection using hydroethedine and DCF-DA, respectively. The increase in hydrogen peroxide level was further confirmed by using the catalase to eliminate its specific fluorescent signal. Surprisingly, cellular nitric oxide level also increased when mitochondrial respiration was suppressed. The increase in nitric oxide could be inhibited by the NOS inhibitor L-NMMA. Biochemical analyses showed total cellular glutathione content and the expression of glutathione peroxidase (GPX-1) protein were elevated in the mitochondrial defective cells, whereas the levels of SOD1 and SOD2 proteins remained unchanged. These alterations in cellular redox states were associated with significant changes (increase or decrease) in cellular sensitivity to anticancer agents, depending on the mechanisms of action of the specific drugs. Compounds with pro-oxidant property are more effective in killing the cells with increased hydrogen peroxide and nitric oxide. These observations may have clinical implications in selecting proper drug to kill cancer cells with mitochondrial dysfunction.

Redox-Cycling "Mitocans" as Effective New Developments in Anticancer Therapy

Tolerable treatment of glioblastoma with redox-cycling 'mitocans': a comparative study in vivo

Prooxidant state in anticancer drugs and prospect use of mitochondrial cofactors and anti-inflammatory agents in cancer prevention

Targeting the Redox Landscape in Cancer Therapy

Metabolic Intervention Mitochondria Nanomotors Breakdown Redox Homeostasis for Boosting Oxidative Stress-Dependent Antitumor Therapy

Amplification of oxidative stress by a dual stimuli-responsive hybrid drug enhances cancer cell death

Cobalt Single-Atom Nanozyme Co-Administration with Ascorbic Acid Enables Redox Imbalance for Tumor Catalytic Ablation

Tissue-Specific Regulation Of Reactive Oxygen Species By An Atp-Responsive Nanoregulator Enhances Anticancer Efficacy And Reduces Anthracycline-Induced Cardiotoxicity

Mitochondrial Respiratory Defects Lead to Significant Alterations in Cellular Redox States and Drug Sensitivity

Polyphenolic Nanomedicine Regulating Mitochondria REDOX for Innovative Cancer Treatment

Simultaneous Targeting of NQO1 and SOD1 Eradicates Breast Cancer Stem Cells via Mitochondrial Futile Redox Cycling

Melanin Nanoparticle-Actuated Redox-State Perturbation and Temporally Photoactivated Thermal Stress for Synergistic Tumor Therapy

Modulating ROS to Overcome Multidrug Resistance in Cancer.

Redox-Based Strategy for Selectively Inducing Energy Crisis Inside Cancer Cells: an Example of Modifying Dietary Curcumin to Target Mitochondria

Mitochondria-specific drug release and reactive oxygen species burst induced by polyprodrug nanoreactors can enhance chemotherapy

Redox regulation and its emerging roles in cancer treatment

Amplification of Oxidative Stress Via Intracellular ROS Production and Antioxidant Consumption by Two Natural Drug-Encapsulated Nanoagents for Efficient Anticancer Therapy

Discovery of proqodine A derivatives with antitumor activity targeting NAD(P)H: quinone oxidoreductase 1 and nicotinamide phosphoribosyltransferase

Regulation of Redox Balance Using a Biocompatible Nanoplatform Enhances Phototherapy Efficacy and Suppresses Tumor Metastasis

Coenzyme-depleting Nanocarriers for Enhanced Redox Cancer Therapy under Hypoxia.

Nanomedicine-based Modulation of Redox Status for Cancer Therapy